$IQST
iQSTEL Inc Stock $iqst

$iqst Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000166357724000224 Filed on August 14, 2024

Income Statement

Concept	2024 Q3	2024 Q2
Revenue	$54.25M	$78.64M
YoY Change	36.45%	139.56%
Cost Of Revenue	$52.23M	$76.47M
YoY Change	34.86%	138.67%
Gross Profit	$2.020M	$2.164M
YoY Change	96.39%	175.81%
Gross Profit Margin	3.72%	2.75%
Selling, General & Admin		$2.352M
YoY Change		146.83%
% of Gross Profit		108.73%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization		$33.78K
YoY Change		-1.89%
% of Gross Profit		1.56%
Operating Expenses	$2.076M	$2.506M
YoY Change	116.8%	141.59%
Operating Profit	-$56.55K	-$342.1K
YoY Change	-179.93%	35.37%
Interest Expense		-$1.612M
YoY Change		-1377.32%
% of Operating Profit
Other Income/Expense, Net	-$646.8K	-$1.557M
YoY Change	2503.63%	-1809.06%
Pretax Income	-$703.4K	-$1.899M
YoY Change	-1506.8%	1074.56%
Income Tax	$69.61K	$65.28K
% Of Pretax Income
Net Earnings	-$773.0K	-$1.964M
YoY Change	1146.52%	817.94%
Net Earnings / Revenue	-1.42%	-2.5%
Basic Earnings Per Share
Diluted Earnings Per Share	-$0.01	-$0.01
COMMON SHARES
Basic Shares Outstanding	183.5M shares	176.8M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2024 Q3	2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments		$797.2K
YoY Change		-29.25%
Cash & Equivalents	$2.125M	$797.2K
Short-Term Investments
Other Short-Term Assets		$1.307M
YoY Change		3628.94%
Inventory	$30.66K	$26.94K
Prepaid Expenses	$1.891M	$1.969M
Receivables	$14.98M	$13.77M
Other Receivables		$1.324M
Total Short-Term Assets	$19.66M	$17.22M
YoY Change	66.82%	142.62%
LONG-TERM ASSETS
Property, Plant & Equipment	$578.7K	$583.3K
YoY Change	24.99%	23.18%
Goodwill	$10.68M	$10.68M
YoY Change	106.43%	106.43%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$992.0K	$979.7K
YoY Change	534.32%	1698.63%
Total Long-Term Assets	$12.77M	$12.77M
YoY Change	101.62%	104.12%
TOTAL ASSETS
Total Short-Term Assets	$19.66M	$17.22M
Total Long-Term Assets	$12.77M	$12.77M
Total Assets	$32.44M	$29.99M
YoY Change	78.99%	124.58%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$8.757M	$7.507M
YoY Change	118.13%	177.83%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt		$3.555M
YoY Change		1302.48%
Long-Term Debt Due	$3.232M	$2.545M
YoY Change	1178.59%	913.03%
Total Short-Term Liabilities	$24.07M	$22.20M
YoY Change	142.75%	221.17%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities		$214.1K
YoY Change		34.39%
Total Long-Term Liabilities	$283.6K	$214.1K
YoY Change	14.85%	-18.19%
TOTAL LIABILITIES
Total Short-Term Liabilities	$24.07M	$22.20M
Total Long-Term Liabilities	$283.6K	$214.1K
Total Liabilities	$24.35M	$22.41M
YoY Change	139.64%	212.43%
SHAREHOLDERS EQUITY
Retained Earnings	-$29.83M	-$28.90M
YoY Change	14.89%	15.23%
Common Stock	$357.2K	$179.6K
YoY Change	109.85%	9.05%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$8.089M	$7.572M
YoY Change
Total Liabilities & Shareholders Equity	$32.44M	$29.99M
YoY Change	78.99%	124.58%

Cashflow Statement

Concept	2024 Q3	2024 Q2
OPERATING ACTIVITIES
Net Income	-$773.0K	-$1.964M
YoY Change	1146.52%	817.94%
Depreciation, Depletion And Amortization		$33.78K
YoY Change		-1.89%
Cash From Operating Activities		-$2.615M
YoY Change		184.66%
INVESTING ACTIVITIES
Capital Expenditures		$31.81K
YoY Change		-53.9%
Acquisitions
YoY Change
Other Investing Activities		-$1.065M
YoY Change		1486.97%
Cash From Investing Activities		-$1.097M
YoY Change		706.02%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		1.784M
YoY Change		345.94%
NET CHANGE
Cash From Operating Activities		-2.615M
Cash From Investing Activities		-1.097M
Cash From Financing Activities		1.784M
Net Change In Cash		-1.928M
YoY Change		194.54%
FREE CASH FLOW
Cash From Operating Activities		-$2.615M
Capital Expenditures		$31.81K
Free Cash Flow		-$2.647M
YoY Change		167.99%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q2	us-gaap	Long Term Loans Payable LongTermLoansPayable		usd
CY2023Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable		usd
CY2023Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-39255	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-850	usd
CY2023Q4	us-gaap	Loans Payable LoansPayable	259447	usd
CY2024Q2	us-gaap	Other Loans Payable Current OtherLoansPayableCurrent	1092766	usd
CY2023Q4	us-gaap	Other Loans Payable Current OtherLoansPayableCurrent	259447	usd
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2024Q2	us-gaap	Debtor Reorganization Items Gain Loss On Settlement Of Other Claims Net1 DebtorReorganizationItemsGainLossOnSettlementOfOtherClaimsNet1		usd
CY2023Q2	us-gaap	Debtor Reorganization Items Gain Loss On Settlement Of Other Claims Net1 DebtorReorganizationItemsGainLossOnSettlementOfOtherClaimsNet1		usd
	us-gaap	Debtor Reorganization Items Gain Loss On Settlement Of Other Claims Net1 DebtorReorganizationItemsGainLossOnSettlementOfOtherClaimsNet1		usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2024Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToNoncontrollingInterest		usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToNoncontrollingInterest		usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts		usd
	us-gaap	Debtor Reorganization Items Gain Loss On Settlement Of Other Claims Net1 DebtorReorganizationItemsGainLossOnSettlementOfOtherClaimsNet1		usd
	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties		usd
	us-gaap	Asset Acquisition Consideration Transferred Other Assets AssetAcquisitionConsiderationTransferredOtherAssets		usd
	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets		usd
	us-gaap	Payments To Fund Longterm Loans To Related Parties PaymentsToFundLongtermLoansToRelatedParties		usd
	us-gaap	Proceeds From Payments For Long Term Loans For Related Parties ProceedsFromPaymentsForLongTermLoansForRelatedParties		usd
	us-gaap	Increase Decrease In Notes Payable Related Parties IncreaseDecreaseInNotesPayableRelatedParties		usd
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt		usd
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt		usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther		usd
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
	IQST	Note Payable Issued For Acquisition Of Subsidiary NotePayableIssuedForAcquisitionOfSubsidiary		usd
	IQST	Contingent Liability For Acquisition Of Subsidiary ContingentLiabilityForAcquisitionOfSubsidiary		usd
CY2024Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent		usd
CY2024Q2	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable		usd
CY2023Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable		usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber		shares
CY2023Q4	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures		shares
	IQST	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms Of Forfeited ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsOfForfeited
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments		usd
CY2023Q4	us-gaap	Derivative Fair Value Of Derivative Net DerivativeFairValueOfDerivativeNet		usd
CY2024Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1200000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1200000	shares
CY2024Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	179557200	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	179557200	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	172129630	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	172129630	shares
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	179557	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	172130	usd
CY2024Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	35947882	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	34360884	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-28902052	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-26084133	usd
CY2024Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-25340	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-25340	usd
CY2024Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	7200088	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	8423582	usd
CY2024Q2	us-gaap	Minority Interest MinorityInterest	-371791	usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest	377710	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	7571879	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	8045872	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	29986660	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	22155653	usd
CY2024Q2	us-gaap	Revenues Revenues	78635764	usd
CY2023Q2	us-gaap	Revenues Revenues	32824829	usd
	us-gaap	Revenues Revenues	130050642	usd
	us-gaap	Revenues Revenues	57491358	usd
CY2024Q2	us-gaap	Cost Of Revenue CostOfRevenue	76472140	usd
CY2023Q2	us-gaap	Cost Of Revenue CostOfRevenue	32040363	usd
	us-gaap	Cost Of Revenue CostOfRevenue	126507992	usd
	us-gaap	Cost Of Revenue CostOfRevenue	55490156	usd
CY2024Q2	us-gaap	Gross Profit GrossProfit	2163624	usd
CY2023Q2	us-gaap	Gross Profit GrossProfit	784466	usd
	us-gaap	Gross Profit GrossProfit	3542650	usd
	us-gaap	Gross Profit GrossProfit	2001202	usd
CY2024Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2505727	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1037184	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4068205	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2571450	usd
CY2024Q2	us-gaap	Operating Expenses OperatingExpenses	2505727	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	1037184	usd
	us-gaap	Operating Expenses OperatingExpenses	4068205	usd
	us-gaap	Operating Expenses OperatingExpenses	2571450	usd
CY2024Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-342103	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-252718	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-525555	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-570248	usd
CY2024Q2	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	55524	usd
CY2023Q2	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	4164	usd
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	127301	usd
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	519	usd
CY2024Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-443	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-73209	usd
CY2024Q2	IQST	Interest Expense2 InterestExpense2	496080	usd
CY2023Q2	IQST	Interest Expense2 InterestExpense2	20103	usd
	IQST	Interest Expense2 InterestExpense2	861554	usd
	IQST	Interest Expense2 InterestExpense2	20103	usd
CY2024Q2	IQST	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss1 FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss1	-1115510	usd
CY2023Q2	IQST	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss1 FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss1	146268	usd
	IQST	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss1 FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss1	-1115510	usd
	IQST	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss1 FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss1	342575	usd
	us-gaap	Debtor Reorganization Items Gain Loss On Settlement Of Other Claims Net1 DebtorReorganizationItemsGainLossOnSettlementOfOtherClaimsNet1	-102660	usd
CY2024Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1556509	usd
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	91074	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1953273	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	249782	usd
CY2024Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1898612	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-161644	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2478828	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-320466	usd
CY2024Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	65275	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	65275	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-1963887	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-161644	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2544103	usd
	us-gaap	Net Income Loss NetIncomeLoss	-320466	usd
CY2024Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	44265	usd
CY2023Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	52301	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	273816	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	256664	usd
CY2024Q2	us-gaap	Net Income Loss Attributable To Parent Diluted NetIncomeLossAttributableToParentDiluted	-2008152	usd
CY2023Q2	us-gaap	Net Income Loss Attributable To Parent Diluted NetIncomeLossAttributableToParentDiluted	-213945	usd
	us-gaap	Net Income Loss Attributable To Parent Diluted NetIncomeLossAttributableToParentDiluted	-2817919	usd
	us-gaap	Net Income Loss Attributable To Parent Diluted NetIncomeLossAttributableToParentDiluted	-577130	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-1963887	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-161644	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2544103	usd
	us-gaap	Net Income Loss NetIncomeLoss	-320466	usd
CY2023Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToNoncontrollingInterest	-2993	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToNoncontrollingInterest	-4570	usd
CY2024Q2	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-1963887	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-158651	usd
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-2544103	usd
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-315896	usd
CY2024Q2	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	44265	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	53767	usd
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	273816	usd
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	258903	usd
CY2024Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2008152	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-212418	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2817919	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-574799	usd
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00
CY2024Q2	IQST	Weighted Average Number Of Share Outstanding Basic WeightedAverageNumberOfShareOutstandingBasic	178445909	shares
CY2023Q2	IQST	Weighted Average Number Of Share Outstanding Basic WeightedAverageNumberOfShareOutstandingBasic	164636688	shares
	IQST	Weighted Average Number Of Share Outstanding Basic WeightedAverageNumberOfShareOutstandingBasic	176799415	shares
	IQST	Weighted Average Number Of Share Outstanding Basic WeightedAverageNumberOfShareOutstandingBasic	164346860	shares
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	8045872	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	31065	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	279660	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	597777	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-580216	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	8374158	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	46600	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	400000	usd
CY2024Q2	IQST	Resolution Of Derivative Liabilities Value ResolutionOfDerivativeLiabilitiesValue	239323	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	475685	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-1963887	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	7571879	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	5835417	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	400000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	11230	usd
CY2023Q1	IQST	Resolution Of Derivative Liabilities Value ResolutionOfDerivativeLiabilitiesValue	240258	usd
CY2023Q1	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	1577	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-158822	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	6329660	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	6900	usd
CY2023Q2	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	2993	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-161644	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	6177909	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2544103	usd
	us-gaap	Net Income Loss NetIncomeLoss	-320466	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	77665	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	18130	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	1801	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	68939	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	68488	usd
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	468797	usd
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	7226	usd
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	1115510	usd
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-342575	usd
	us-gaap	Debtor Reorganization Items Gain Loss On Settlement Of Other Claims Net1 DebtorReorganizationItemsGainLossOnSettlementOfOtherClaimsNet1	-102660	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-12944081	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	589928	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	185	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1995	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	500544	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	75867	usd
	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	-46631	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-9519447	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	1144422	usd
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-5367232	usd
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-675466	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3151688	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-721400	usd
	us-gaap	Asset Acquisition Consideration Transferred Other Assets AssetAcquisitionConsiderationTransferredOtherAssets	-2505121	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	103474	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	132249	usd
	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets	-149537	usd
	us-gaap	Payments To Fund Longterm Loans To Related Parties PaymentsToFundLongtermLoansToRelatedParties	111602	usd
	us-gaap	Proceeds From Payments For Long Term Loans For Related Parties ProceedsFromPaymentsForLongTermLoansForRelatedParties	2700	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2720197	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-279086	usd
	us-gaap	Proceeds From Other Debt ProceedsFromOtherDebt	699525	usd
	us-gaap	Proceeds From Other Debt ProceedsFromOtherDebt	150000	usd
	us-gaap	Repayments Of Other Debt RepaymentsOfOtherDebt	147253	usd
	us-gaap	Repayments Of Other Debt RepaymentsOfOtherDebt	9006	usd
	us-gaap	Increase Decrease In Notes Payable Related Parties IncreaseDecreaseInNotesPayableRelatedParties	1000000	usd
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	-166681	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	400000	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	400000	usd
	us-gaap	Proceeds From Issuance Of Medium Term Notes ProceedsFromIssuanceOfMediumTermNotes	3722500	usd
	us-gaap	Proceeds From Issuance Of Medium Term Notes ProceedsFromIssuanceOfMediumTermNotes	250000	usd
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	-301647	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5306444	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	790994	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6873	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-565441	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-202619	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1362668	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1329389	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	797227	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1126770	usd
	us-gaap	Interest Paid Net InterestPaidNet	289493	usd
	us-gaap	Interest Paid Net InterestPaidNet	6600	usd
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	279660	usd
	IQST	Resolution Of Derivative Liabilities Value ResolutionOfDerivativeLiabilitiesValue	239323	usd
	IQST	Resolution Of Derivative Liabilities Value ResolutionOfDerivativeLiabilitiesValue	240258	usd
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	597777	usd
	IQST	Note Payable Issued For Acquisition Of Subsidiary NotePayableIssuedForAcquisitionOfSubsidiary	2000000	usd
	IQST	Contingent Liability For Acquisition Of Subsidiary ContingentLiabilityForAcquisitionOfSubsidiary	1000000	usd
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Incorporation Date Of Incorporation EntityIncorporationDateOfIncorporation	2011-06-24
	us-gaap	Reclassifications Reclassifications	<p id="xdx_84D_eus-gaap--Reclassifications_zlAzC0CEHoB7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Reclassification</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Certain accounts from prior periods have been reclassified to conform to the current period presentation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84C_eus-gaap--UseOfEstimates_zoHxn4VPSe5i" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Use of Estimates</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The preparation of the consolidated financial statements in conformity with GAAP in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. The estimates and judgments will also affect the reported amounts for certain revenues and expenses during the reporting period. Actual results could differ from these good faith estimates and judgments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	797227	usd
CY2023Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	1362668	usd
	us-gaap	Allowance For Loan And Lease Loss Recovery Of Bad Debts AllowanceForLoanAndLeaseLossRecoveryOfBadDebts	1801	usd
	us-gaap	Allowance For Loan And Lease Loss Recovery Of Bad Debts AllowanceForLoanAndLeaseLossRecoveryOfBadDebts	0	usd
CY2024Q2	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	150726	usd
CY2023Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	312116	usd
CY2024Q2	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	1285619	usd
CY2023Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	738050	usd
CY2024Q2	us-gaap	Advances On Inventory Purchases AdvancesOnInventoryPurchases	21000	usd
CY2023Q4	us-gaap	Advances On Inventory Purchases AdvancesOnInventoryPurchases	21000	usd
CY2024Q2	us-gaap	Income Tax Receivable IncomeTaxReceivable	25607	usd
CY2023Q4	us-gaap	Income Tax Receivable IncomeTaxReceivable	428	usd
CY2024Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents	357500	usd
CY2023Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents	357500	usd
CY2024Q2	us-gaap	Security Deposit SecurityDeposit	128703	usd
CY2023Q4	us-gaap	Security Deposit SecurityDeposit	20000	usd
CY2024Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1969155	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1449094	usd
CY2024Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1506218	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1323432	usd
CY2024Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	922904	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	800435	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	583314	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	522997	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	68939	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	68488	usd
CY2024Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	2688075	usd
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	367837	usd
CY2024Q2	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	143197	usd
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	3750	usd
CY2024Q2	us-gaap	Long Term Debt LongTermDebt	2544878	usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	364087	usd
CY2024Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	2544878	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	264988	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	99099	usd
	us-gaap	Repayments Of Other Debt RepaymentsOfOtherDebt	147253	usd
	us-gaap	Repayments Of Other Debt RepaymentsOfOtherDebt	9006	usd
	us-gaap	Debtor Reorganization Items Gain Loss On Settlement Of Other Claims Net1 DebtorReorganizationItemsGainLossOnSettlementOfOtherClaimsNet1	-102660	usd
CY2024Q2	us-gaap	Loans Payable LoansPayable	1092766	usd
CY2024Q2	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	4281906	usd
CY2023Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	369044	usd
CY2024Q2	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	3555006	usd
CY2023Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	330032	usd
CY2024Q2	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	3555006	usd
CY2023Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	330032	usd
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	7427570	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	179557200	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	179557200	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	172129630	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	172129630	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1200000	shares
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q2	us-gaap	Loans And Leases Receivable Related Parties LoansAndLeasesReceivableRelatedParties	661087	usd
CY2023Q4	us-gaap	Loans And Leases Receivable Related Parties LoansAndLeasesReceivableRelatedParties	340515	usd
CY2023Q4	us-gaap	Notes And Loans Payable Current NotesAndLoansPayableCurrent	26613	usd
	us-gaap	Management Fee Expense ManagementFeeExpense	423000	usd
	us-gaap	Management Fee Expense ManagementFeeExpense	270000	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	77665	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	18130	usd
CY2024Q2	us-gaap	Financial Guarantee Insurance Contracts Risk Management Activities Mitigating Claim Liabilities Accrued Liabilities FinancialGuaranteeInsuranceContractsRiskManagementActivitiesMitigatingClaimLiabilitiesAccruedLiabilities	205627	usd
CY2023Q4	us-gaap	Financial Guarantee Insurance Contracts Risk Management Activities Mitigating Claim Liabilities Accrued Liabilities FinancialGuaranteeInsuranceContractsRiskManagementActivitiesMitigatingClaimLiabilitiesAccruedLiabilities	100128	usd
CY2024Q2	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P12M
	us-gaap	Operating Lease Expense OperatingLeaseExpense	14028	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	2137	usd
CY2024Q2	us-gaap	Revenues Revenues	78635764	usd
CY2024Q2	us-gaap	Cost Of Revenue CostOfRevenue	76472140	usd
CY2024Q2	us-gaap	Gross Profit GrossProfit	2163624	usd
CY2024Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2505727	usd
CY2024Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-342103	usd
CY2024Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1556509	usd
CY2024Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	65275	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-1963887	usd
CY2023Q2	us-gaap	Revenues Revenues	32824829	usd
CY2023Q2	us-gaap	Cost Of Revenue CostOfRevenue	32040363	usd
CY2023Q2	us-gaap	Gross Profit GrossProfit	784466	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1037184	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-252718	usd
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	91074	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-161644	usd
	us-gaap	Revenues Revenues	130050642	usd
	us-gaap	Cost Of Revenue CostOfRevenue	126507992	usd
	us-gaap	Gross Profit GrossProfit	3542650	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4068205	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-525555	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1953273	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	65275	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2544103	usd
	us-gaap	Revenues Revenues	57491358	usd
	us-gaap	Cost Of Revenue CostOfRevenue	55490156	usd
	us-gaap	Gross Profit GrossProfit	2001202	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2571450	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-570248	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	249782	usd
	us-gaap	Net Income Loss NetIncomeLoss	-320466	usd
CY2024Q2	us-gaap	Assets Current AssetsCurrent	17220260	usd
CY2024Q2	us-gaap	Assets Noncurrent AssetsNoncurrent	12766400	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	22200638	usd
CY2024Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	214143	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	15719172	usd
CY2023Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	6436481	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13840944	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	268837	usd
	us-gaap	Derivatives Reporting Of Derivative Activity DerivativesReportingOfDerivativeActivity	<p id="xdx_80B_eus-gaap--DerivativesReportingOfDerivativeActivity_z9DA9siG5xX7" style="font: 10.5pt/107% Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 13 – WARRANTS</b></span></p> <p style="font: 10.5pt/107% Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10.5pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 12, 2024, we issued a Common Stock Purchase Option (the “Option”) to ADI Funding LLC (“ADI Funding”) for <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20240212__us-gaap--DebtInstrumentAxis__custom--ADIFundingLLCMember_zYKi1LhWwn5g">$100,000</span> that expires on December 31, 2024, for the right to acquire up to <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20240212__20240212__us-gaap--DebtInstrumentAxis__custom--ADIFundingLLCMember_zaXUpGXXleTa">10,000,000</span> shares of common stock. <span id="xdx_905_eus-gaap--DebtInstrumentCallFeature_c20240212__20240212__us-gaap--DebtInstrumentAxis__custom--ADIFundingLLCMember_zkP94Ly3TJH2">The exercise price per share of the common stock under the Option shall be (i) 70% of the VWAP of the common stock during the then 10 Trading Days immediately preceding, but not including the date of exercise if the VWAP is below $2.00 or (ii) seventy five percent (75%) of the VWAP of the common stock during the then 10 Trading Days immediately preceding, but not including the date of exercise if the VWAP is equal or above $2.00.</span></span></p> <p style="font: 10.5pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10.5pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--OptionIndexedToIssuersEquitySettlementAlternatives_c20240212__20240212__us-gaap--DebtInstrumentAxis__custom--ADIFundingLLCMember_zQFwrzS1kwUg">ADI Funding has the right and the obligation to exercise, on a “cash basis”, not less than (i) 2,000,000 of the shares of common stock underlying the option not later than the later of March 31, 2024 or the date on which there is an effective registration statement permitting the resale of the shares by ADI Funding. From and after the occurrence of the above-referenced exercise, each additional exercise of the Option shall be in an amount not less than 1,000,000 shares, which shall occur every thirty (30) days and shall be exercised only on a cash basis. ADI Funding’s obligation to exercise each specified portion of the Option is subject to the exercise price being not less than $0.11</span></span></p> <p style="font: 10.5pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10.5pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the Company issues securities less than the exercise price of the option, ADI Funding has a right to also use that lesser price in the exercise of its Option. The Option also contains rights to any company distributions and consideration in fundamental transactions.</span></p> <p style="font: 10.5pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10.5pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in FASB ASC 480, Distinguishing Liabilities from Equity (“ASC 480”) and ASC 815, Derivatives and Hedging (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own common shares and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.</span></p> <p style="font: 10.5pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10.5pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company determined that the warrants had net cash settlement and categorized the warrants as a liability in the accompanying consolidated financial statements.</span></p> <p style="font: 10.5pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10.5pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of activity regarding warrants issued as follows:</span></p> <p style="font: 10.5pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zU5q8r8C5R5f" style="font: 11pt Calibri, Helvetica, Sans-Serif; margin-left: auto; border-collapse: collapse; width: 40%; margin-right: auto" summary="xdx: Disclosure - NOTE 13 - WARRANTS - Schedule of Warrant Summary (Details)"> <tr> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average Remaining</b></span></td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td><td style="text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants outstanding</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual life (in years)</b></span></td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="3"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="3"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding, December 31, 2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20231231_zmwYJ4Bkuy0a"><span style="-sec-ix-hidden: xdx2ixbrl1396">—</span></span> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_d0_c20231231_z9YXDu0qi9X4"><span style="-sec-ix-hidden: xdx2ixbrl1397">—</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; width: 27%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 26%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20240101__20240630_z7eSBdqzOi86">10,000,000</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 26%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_ecustom--WeightedAverageRemainingLifeOfWarrantsGrantedInPeriod_dtY_c20240101__20240630_zEpM76Ox7ev1">0.88</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20240101__20240630_zY8aT9Ycyyv8">1,822,216</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20240101__20240630_zKSFEtGgp256"><span style="-sec-ix-hidden: xdx2ixbrl1401">—</span></span> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited/canceled</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20240101__20240630_zHZ4xxN1Vgq5"><span style="-sec-ix-hidden: xdx2ixbrl1402">—</span></span> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsOfForfeited_d0_c20240101__20240630_zbtA6ZU76Ce6"><span style="-sec-ix-hidden: xdx2ixbrl1403">—</span></span> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding, June 30, 2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20240630_zi2iYEJgSdO9">8,177,784</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240630_z1D5aoJWit9h">0.50</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p style="margin-top: 0; margin-bottom: 0"> </p> <p style="margin-top: 0; margin-bottom: 0"></p> <p style="margin-top: 0; margin-bottom: 0"></p> <p style="margin-top: 0; margin-bottom: 0"></p> <p style="margin-top: 0; margin-bottom: 0"></p> <p style="margin-top: 0; margin-bottom: 0"></p> <p style="margin-top: 0; margin-bottom: 0"></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="margin-top: 0; margin-bottom: 0"></p> <p style="font: 10.5pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The intrinsic value of the warrants as of June 30, 2024 is approximately <span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iI_c20240630_zsqzm9XRElvc">$680,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. All of the outstanding warrants are exercisable as of June 30, 2024; however, each exercise is subject to a beneficial ownership limitation of <span id="xdx_901_eus-gaap--VariableInterestEntityOwnershipPercentage_c20240101__20240630_zr9AIZ7v5Ek8">4.99%</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of the Company’s outstanding common stock, which, upon notice, may be increased to <span id="xdx_90E_eus-gaap--VariableInterestEntityOwnershipPercentage_c20240101__20240630__us-gaap--DebtInstrumentAxis__custom--BeneficialOwnershipLimitationUponNoticeMember_zn1cWZl0WDxb">9.99%</span>.</span></p> <p style="font: 10.5pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10.5pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10.5pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Fair Value Assumptions Used in Accounting for Derivative Liabilities</i></span></p> <p style="font: 10.5pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10.5pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC 815 requires we assess the fair market value of derivative liabilities at the end of each reporting period and recognize any change in the fair market value as other income or expense.</span></p> <p style="font: 10.5pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10.5pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10.5pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10.5pt/107% Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company determined our derivative liabilities to be a Level 3 fair value measurement and used the Black-Scholes pricing model to calculate the fair value as of June 30, 2024. The Black-Scholes model requires six basic data inputs: the exercise or strike price, time to expiration, the risk-free interest rate, the current stock price, the estimated volatility of the stock price in the future, and the dividend rate. Changes to these inputs could produce a significantly higher or lower fair value measurement. </span></p> <p style="font: 10.5pt/107% Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p> <p style="font: 10.5pt/107% Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of June 30, 2024, the estimated fair values of the liabilities measured on a recurring basis are as follows:</span></p> <p style="font: 10.5pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10.5pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_88E_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zhnTQUALGim1" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 30%; margin-right: auto" summary="xdx: Disclosure - NOTE 13 - WARRANTS - Schedule of Fair Value Measurement of Liabilities (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: center; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td> <td style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></td><td style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> As of June 30, 2024</b></span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected term</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="width: 28%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240630__20240630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__srt--MinimumMember_zRQ4OoUTljF3">0.50</span> - <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240630__20240630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__srt--MaximumMember_zJmSr7sKfnpd">0.65</span> years </span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise price</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20240630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__srt--MinimumMember_zl1ZPvgISpol">$0.17</span> –<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20240630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__srt--MaximumMember_zU40Gx18Jm82">$0.23</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected average volatility</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_c20240630__20240630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__srt--MinimumMember_zaFs4s4hzSxe">108%</span> - <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_c20240630__20240630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__srt--MaximumMember_z6diDOoaKIVi">117%</span> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected dividend yield</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_pp0p0_c20240630__20240630_zIw01xME1tva"><span style="-sec-ix-hidden: xdx2ixbrl1417">—</span></span> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free interest rate</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_c20240630__20240630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__srt--MinimumMember_znvNXmmO52Ua">5.33%</span> - <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_c20240630__20240630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__srt--MaximumMember_zeT7ZngT4rZ5">5.44%</span> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p style="margin-top: 0; margin-bottom: 0"> </p> <p style="margin-top: 0; margin-bottom: 0"></p> <p style="margin-top: 0; margin-bottom: 0"></p> <p style="margin-top: 0; margin-bottom: 0"></p> <p style="margin-top: 0; margin-bottom: 0"></p> <p style="margin-top: 0; margin-bottom: 0"></p> <p style="margin-top: 0; margin-bottom: 0"></p> <p style="font: 10.5pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10.5pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes the changes in the derivative liabilities during the six months ended June 30, 2024:</span></p> <p style="font: 10.5pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_884_eus-gaap--FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTableTextBlock_zaDdyGGkc80h" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 40%; margin-right: auto" summary="xdx: Disclosure - NOTE 13 - WARRANTS - Fair Value Measurements Using Significant Observable Inputs (Details)"> <tr style="vertical-align: bottom"> <td colspan="5" style="border-bottom: Black 1pt solid; text-align: center">Fair Value Measurements Using Significant Observable Inputs (Level 3)</td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="3" style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance - December 31, 2023</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_pp0p0_c20231231_zJcrbivzc8P4"><span style="-sec-ix-hidden: xdx2ixbrl1422">—</span></span> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 68%; text-align: left; padding-left: 5.4pt">Addition of new derivatives recognized as cash received</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 28%; text-align: right"><span id="xdx_90D_eus-gaap--DebtorReorganizationItemsWriteOffOfDeferredFinancingCostsAndDebtDiscounts_c20240101__20240630_zyrjj1Q2Qyrh">100,000</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="color: #212529; text-align: left; padding-left: 5.4pt">Settled on issuance of common stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(<span id="xdx_900_ecustom--ResolutionOfDerivativeLiabilitiesValue_pp0p0_c20240101__20240630_zXIJvGiSMzV1">239,323</span></td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Change in fair value of derivative liabilities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_901_eus-gaap--DebtSecuritiesHeldToMaturityTransferDerivativeHedgeGainLoss_pp0p0_c20240101__20240630_zx8YZcUoFila">1,115,510</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; padding-left: 5.4pt">Balance - June 30, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_pp0p0_c20240630_zWwLlnSZoqVd">976,187</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10.5pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	10000000	shares
	IQST	Weighted Average Remaining Life Of Warrants Granted In Period WeightedAverageRemainingLifeOfWarrantsGrantedInPeriod	P0Y10M17D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	1822216	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	8177784	shares
CY2024Q2	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P0Y6M
CY2024Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding	680000	usd
	us-gaap	Variable Interest Entity Ownership Percentage VariableInterestEntityOwnershipPercentage	0.0499	pure
	us-gaap	Debtor Reorganization Items Write Off Of Deferred Financing Costs And Debt Discounts DebtorReorganizationItemsWriteOffOfDeferredFinancingCostsAndDebtDiscounts	100000	usd
	IQST	Resolution Of Derivative Liabilities Value ResolutionOfDerivativeLiabilitiesValue	239323	usd
	us-gaap	Debt Securities Held To Maturity Transfer Derivative Hedge Gain Loss DebtSecuritiesHeldToMaturityTransferDerivativeHedgeGainLoss	1115510	usd
CY2024Q2	us-gaap	Derivative Fair Value Of Derivative Net DerivativeFairValueOfDerivativeNet	976187	usd

Files In Submission

Name	View Source	Status
0001663577-24-000224-index-headers.html	Edgar Link	pending
0001663577-24-000224-index.html	Edgar Link	pending
0001663577-24-000224.txt	Edgar Link	pending
0001663577-24-000224-xbrl.zip	Edgar Link	pending
ex31_1.htm	Edgar Link	pending
ex31_2.htm	Edgar Link	pending
ex32_1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
iqst-20240630.xsd	Edgar Link	pending
iqst10q2_063024.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
iqst10q2_063024_htm.xml	Edgar Link	completed
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
iqst-20240630_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
iqst-20240630_def.xml	Edgar Link	unprocessable
iqst-20240630_lab.xml	Edgar Link	unprocessable
iqst-20240630_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$IQST
iQSTEL Inc Stock $iqst

2024 Q3 Form 10-Q Financial Statement

#000166357724000224 Filed on August 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IQST iQSTEL Inc Stock $iqst

2024 Q3 Form 10-Q Financial Statement

#000166357724000224 Filed on August 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IQST
iQSTEL Inc Stock $iqst